NCT04691011Completed
New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Our project aims to find new biomarkers in MRI at three levels: cerebral, medullary and muscular. These markers could allow an earlier diagnosis of the disease by showing more specific lesions of ALS and to quantify these lesions to measure the progression of the disease. This study will use advanced Magnetic Resonance Imaging (MRI) techniques High field (3T) and very high field (7T) MRI. Results from neurological and electrophysiological tests will be compared to the MRI. Subjects will be recruited from ALS center of Marseille, France. MRI will be done on ALS patients at baseline, at 3 month and at 6 month intervals.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 22 (actual)
- First submitted
- 22 Oct 2020
- Start date
- 16 Jun 2021
- Primary completion date
- 4 Jun 2025
- Lead sponsor
- Assistance Publique Hopitaux De Marseille
- Diseases
- ALS (motor neurone disease)
- NCT number
- NCT04691011
What you commit to
- Study type: Interventional
- Participants enrolled: 22
- From 16 Jun 2021 to the primary completion date, 4 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects with other psychiatric or CNS or PNS diseases.
Other
- Subjects ineligible for MRI investigation due to a pacemaker or other metallic foreign body, or significant claustrophobia that could affect the ability to have an MRI scan.
Who the study is looking for
- Patients will be adults with a diagnosis of ALS.
- Healthy controls will also be recruited and will be age- and gender-matched to patients.
- Patients able to undergo a brain MRI for approximately an hour.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shahram Attarian Coordinator of this site? Confirm its status | Marseille | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.